Alembic Pharma gets USFDA nod for generic product

Alembic Pharmaceuticals has received approval from the USFDA to market Albendazole Tablets USP (200 mg), a generic drug for treating infections caused by worms. The tablets are equivalent to Impax Laboratories' Albenza and are used for conditions like parenchymal neurocysticercosis and cystic hydatid disease. Alembic Pharma shares rose 2.79% on Thursday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tl8GQaC
via IFTTT